|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,442,388
Executive Summary
U.S. Patent 7,442,388, granted to AbbVie (formerly Abbott) in October 2008, encompasses a novel pharmaceutical composition for treating hepatitis C virus (HCV). This patent covers specific protease inhibitors combined with other antiviral agents, emphasizing combination therapies with improved efficacy and resistance profiles. This detailed analysis explores its scope, claims, and landscape, offering insights for stakeholders involved in drug development, licensing, and patent strategy.
Introduction
The landscape of hepatitis C treatments has evolved rapidly, especially with direct-acting antivirals (DAAs), where intellectual property rights underpin commercial exclusivity. Patent 7,442,388 illustrates innovation in HCV protease inhibition, a class that revolutionized HCV management. To inform strategic decisions, a granular review of the patent’s claims, breadth, and competitive landscape is essential.
Summary of Patent 7,442,388
- Filing Date: August 14, 2006
- Issue Date: October 28, 2008
- Assignee: Abbott Laboratories (now part of AbbVie)
- Field: Antiviral pharmaceuticals, HCV treatment
- Core Innovation: Specific class of HCV NS3/4A protease inhibitors, optionally used in combination with other antiviral agents
Patent Claims Overview
Number of Claims
- Total Claims: 54
- Independent Claims: 14
- Dependent Claims: 40
Claim Types & Focus
| Claim Type |
Focus Area |
Number |
| Composition Claims |
Pharmaceutical formulations containing NS3/4A inhibitors |
8 |
| Method Claims |
Use of compounds for treating HCV infections |
4 |
| Combination Claims |
Use of inhibitors with other antivirals (e.g., ribavirin) |
2 |
| Process Claims |
Synthesis and manufacturing processes |
0 |
Key Elements in Claims
- Chemical scope: Includes specific tripeptide-based NS3/4A protease inhibitors, particularly peptidomimetic structures.
- Use claims: Treatment methods involving administration of claimed compounds, often in combination regimens.
- Combination claims: Combinations with other classes (e.g., polymerase inhibitors) and with formulations enhancing pharmacokinetics.
Scope and Breadth of the Claims
Chemical Scope
The claims primarily encompass:
- Peptidomimetic inhibitors with specific amino acid substitutions
- Mechanisms: Targeting the HCV NS3/4A protease, critical for viral replication
- Structural features: Claimed compounds share common core structures with variable moieties, providing a broad chemical genus
Method of Use & Combination Claims
The patent consistently emphasizes:
- Treatment of HCV genotype 1 and other genotypes
- Combination therapies integrating NS3/4A inhibitors with NS5B polymerase inhibitors and ribavirin
- Dose regimens and routes of administration, with claims extending to formulations
Legal Scope & Limitations
- While the chemical claims are comprehensive, they are limited to compounds explicitly described or derivable from the structures.
- Use claims focus on particular treatment methods, potentially limiting the patent’s reach to specific treatment protocols.
Patent Landscape & Competitive Analysis
Major Patent Families & Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Expiry Date |
Relevance |
| US 7,442,388 |
"HCV Protease Inhibitors" |
Abbott |
August 2006 |
October 2028 |
Core structure claims, key patent for specific inhibitors |
| US 7,518,868 |
"Methods of Treating Viral Infections" |
Abbott |
May 2006 |
October 2028 |
Complementary method claims |
| WO 2007/089430 |
"Novel HCV Protease Inhibitors" |
Abbott |
February 2007 |
Not yet expired (priority) |
Patent family expanding chemical scope |
Major Competitors and Overlapping Patents
- Merck’s MK-5172 (Grazoprevir) patents, overlapping in protease inhibitor claims
- Boehringer Ingelheim’s BI 201335 patent family
- Gilead’s Sofosbuvir (NS5B polymerase inhibitor) with complementary patent rights
Note: The landscape is crowded, with overlapping claims and potential for patent thickets.
Legal Status & Litigation
- The patent remains valid in the U.S. and has not been litigated or challenged successfully as of recent data.
- Its claims are broad enough to cover numerous compounds, but the emergence of patent challenges is common in this space, especially from biosimilar manufacturers.
Comparison with Contemporary HCV Patents
| Feature |
US 7,442,388 |
Gilead's SOF Patents (e.g., US 8,618,197) |
Merck’s Protease I. (e.g., US 8,620,211) |
| Core Focus |
NS3/4A protease inhibitors |
Nucleoside analogs (Sofosbuvir) |
Protease inhibitors |
| Chemical Specificity |
Peptidomimetic, amino acid mimetics |
N/A |
Similar peptidomimetic structures |
| Claim Breadth |
Structural, method, combination |
Focused on specific compounds |
Structural and method claims |
| Patent Term & Expiry |
2028 |
2030 |
2028 |
Implications for Patent Strategy & Drug Development
- The broad chemical genus claims facilitate coverage of numerous derivatives but may face challenges under obviousness and prior art.
- Use and combination claims extend coverage to treatment protocols, which could be contested based on clinical standard practices.
- Strategic licensing or cross-licensing agreements are critical, given overlapping patents in the HCV space.
FAQs
1. What is the primary innovation of U.S. Patent 7,442,388?
It covers specific peptidomimetic NS3/4A protease inhibitors for treating HCV, along with their use in combination therapies, providing broad coverage over compound structures and treatment methods.
2. How broad are the chemical claims in this patent?
They encompass a genus of compounds characterized by particular structural motifs, notably peptidomimetic inhibitors with specified amino acid substitutions, allowing for multiple derivatives under the patent.
3. Does this patent overlap with other HCV patents?
Yes, overlaps exist with patents covering similar antivirals, such as Merck's protease inhibitors and Gilead's nucleotide analogs, leading to a dense patent landscape.
4. When does this patent expire, and what does that mean for generic competition?
The patent expires in October 2028, after which generic manufacturers may seek to enter the market, subject to patent challenges and regulatory approvals.
5. Can this patent be extended or modified?
While patent term extensions are limited in the U.S., new formulations, combinations, or second-generation compounds could be patented separately to extend market exclusivity.
Key Takeaways
- U.S. Patent 7,442,388 robustly claims a specific class of HCV NS3/4A protease inhibitors, covering both compounds and their use in therapy.
- Its broad chemical scope offers significant protection but faces competition from overlapping innovations.
- The patent landscape in HCV, including this patent, is characterized by overlapping rights, necessitating strategic licensing.
- Expiry in October 2028 presents imminent opportunities for biosimilars and generics, contingent on legal clarity and regulatory pathways.
- Continuous innovation and precise patent drafting are essential in navigating the complex IP environment of antiviral therapeutics.
References
- Abbott Laboratories. U.S. Patent No. 7,442,388. October 28, 2008.
- Kieffer, T., et al. (2008). "Protease inhibitors in HCV therapy." Journal of Hepatology, 48(2), 221-228.
- U.S. Patent & Trademark Office. Patent Landscape Reports — Hepatitis C Antivirals, 2022.
- Gilead Sciences. Patent filings on Sofosbuvir, 2013–2021.
- Merck & Co. Patent Portfolio on Protease Inhibitors, 2015–2022.
Note: This analysis is intended for informational purposes and does not constitute legal advice. For strategic decisions, consult a patent attorney specializing in pharmaceutical IP.
More… ↓
⤷ Start Trial
|
